Thimerosal and the relevance of patch-test reactions in children

Dermatitis

Volumn 19, Issue 5, 2008, Pages 275-277

  Breithaupt, Andrew ^a,b   Jacob, Sharon E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; PRESERVATIVE; THIOMERSAL; VACCINE;

ARTICLE; CHILD; HUMAN; PATCH TEST; SKIN ALLERGY;

ALLERGENS; CHILD; DERMATITIS, ALLERGIC CONTACT; HUMANS; PATCH TESTS; PRESERVATIVES, PHARMACEUTICAL; THIMEROSAL; VACCINES;

EID: 58149348429     PISSN: 17103568     EISSN: 21625220     Source Type: Journal    
DOI: 10.2310/6620.2008.08028     Document Type: Article

References (18)

1. Herbst RA, Uter W, Pirker C, et al. Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5-year period. Contact Dermatitis 2004;51:13-9. (Pubitemid 39127948)
2. Suneja T, Belsito DV. Thimerosal in the detection of clinically relevant allergic contact reactions. J Am Acad Dermatol 2001;45:23-7. (Pubitemid 32655688)
3. Marks JG, Belsito DV, De Leo VA, et al. North American Contact Dermatitis Group patch-test results, 1998-2000. Am J Contact Dermat 2003;14:59-62. (Pubitemid 36988512)
4. Krob HA, Fleischer AB, D'Agostino R, et al. Prevalence and relevance of contact dermatitis allergens: a meta-analysis of 15 years of published T. R. U. E. test data. J Am Acad Dermatol 2004;51:346-53.
5. Belsito DV. Thimerosal: contact (non) allergen of the year. Am J Contact Dermat 2002;13:1-2. (Pubitemid 34205621)
6. Marks JG, Belsito DV, De Leo VA, et al. North American Contact Dermatitis Group patch test results for the detection of delayedtype hypersensitivity to topical allergens. J Am Acad Dermatol 1998;36:911-8. (Pubitemid 28299182)
7. Jacob SE, Brod BA, Crawford GH. Clinically relevant patch test reactions in children-a United States based study. Pediatric Dermatology Journal [In press]
8. Centers for Disease Control. Thimerosal in vaccines. May 12, 2008. Available at: http://www.fda.gov/cber/vaccine/thimerosal.htm (accessed May 25, 2008).
9. Aberer W. Vaccination despite thimerosal sensitivity. Contact Dermatitis 1991;24:6-10.
10. Audicana MT, Munoz D, Del Pozo MD, et al. Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thimerosal. Am J Contact Dermat 2002;13:3-9. (Pubitemid 34205622)
11. Cox NH, Forsyth A. Thimerosal allergy and vaccination reactions. Contact Dermatitis 1988;18:229-33.
12. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001;107:1147-54. (Pubitemid 32440625)
13. Baker JP. Mercury, vaccines, and autism: one controversy, three histories. Am J Public Health 2008;98:244-53. (Pubitemid 351320502)
14. Ames SJ, Slikker W III, Melnyk S, et al. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology 2005;26:1-8. (Pubitemid 39440960)
15. Geier DA, Geier MR. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 2006;27:401-13. (Pubitemid 46043595)
16. Centers for Disease Control. Mercury and vaccines (thimerosal). January 8, 2007. Available at: http://www.cdc.gov/od/science/iso/concerns/thimerosal.htm (accessed April 1, 2008).
17. World Health Organization. Thimerosal vaccines: questions and answers. July 2006. Available at: http://www.who.int/vaccine-safety/topics/thiomersal/ questions/en/ (accessed April 1, 2008).
18. Center for Biologics Evaluation and Research, U. S. Food and Drug Administration. Thimerosal in vaccines, September 6, 2007; Available at: http://www.fda.gov/cber/vaccine/thimerosal.htm (accessed April 1, 2008).